Skip to main content
Fig. 6 | Acta Neuropathologica Communications

Fig. 6

From: Longitudinal multiomics analysis of aggressive pituitary neuroendocrine tumors: comparing primary and recurrent tumors from the same patient, reveals genomic stability and heterogeneous transcriptomic profiles with alterations in metabolic pathways

Fig. 6

Panel A GH3 cells without any treatment as control (Cn), panel A1 GH3 cells with DMSO vehicle only, both, showing no apoptosis induction; panels A2, A3, and A4 apoptosis induction by dasatinib treatment at 1, 2.5 and 5 μM concentrations. Panel A5 graph statistical results from dasatinib treatments. Panels B–B5 and C–C5 no apoptosis induction by imatinib and nilotinib, respectively. Panel D GH3 cell culture without any TKI treatment whereby 31.3% of live cells show proliferation; imatinib treatment did not result in any reduction in proliferation, panels E–E2. nilotinib treatment showed 12–22% reduction of cell proliferation F–F2 panels. dasatinib induces a 28% and 98% reduction of cell proliferation at different concentrations, panels G–G2

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us